Adherium to Supply AstraZeneca Australia With Smartinhaler™ Platform for a Joint Commercial Pilot Program

MELBOURNE, Australia, Aug. 16, 2016 (GLOBE NEWSWIRE) -- Adherium Limited (ASX:ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced that Adherium will provide Smartinhalers for an AstraZeneca Australia commercial pilot program in 2016. The program will use Adherium’s devices, mobile app and cloud platform and aims to show how these devices improve medication adherence in patients with asthma and chronic obstructive pulmonary disease (COPD).

“This program is an important milestone; adherence rates in patients with asthma or COPD are low, and clinical trials have demonstrated that our platform can make a significant difference for patients and health care professionals. Adherium is supplying the technology for this program under a long-term Master Supply and Development Agreement already entered into with AstraZeneca,” said Garth Sutherland, Adherium’s Group CEO.


Adherium (ASX:ADR) is an Australian Securities Exchange listed company which develops, manufactures and supplies digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease. Adherium operates globally from bases in the USA, Europe and Australasia.

Adherium is a provider of digital health solutions to patients, pharmaceutical companies, healthcare providers and contract research organizations. The Company’s proprietary Smartinhaler™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease. Adherium has the broadest range of "smart" medication sensors for respiratory medications globally.

The Smartinhaler™ platform has so far been used in more than 65 projects (clinical, device validation or other) and has been referenced in 56 peer reviewed journal articles. Clinical outcomes data has proven that the Smartinhaler™ platform can improve adherence by up to 59% in adults and 180% in children and reduce severe episodes by 60% in adults, leading to improved quality-of-life and demonstrating a substantial gain over current best practice treatment. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.


At Adherium:
Julia Chambers
Head of Corporate Development
M: +64 27 807 8153
North America
James Hattersley
SVP Business Development North America
M: +1 610 955 5886
Media enquiries:
Australia and New Zealand
Rudi Michelson
Monsoon Communications
D: +61 3 9620 3333
North America
Erich Sandoval
Lazar Partners
D: +1 213-908-6226

Source: Adherium